Published online Jul 24, 2024. doi: 10.5306/wjco.v15.i7.895
Revised: May 11, 2024
Accepted: June 6, 2024
Published online: July 24, 2024
Processing time: 140 Days and 19.6 Hours
Parthenolide (PTL), a sesquiterpene lactone derived from the medicinal herb Chrysanthemum parthenium, exhibits various biological effects by targeting NF-kB, STAT3, and other pathways. It has emerged as a promising adjunct therapy for multiple malignancies.
To evaluate the in vitro and in vivo effect of PTL on cyclophosphamide (CTX) metronomic chemotherapy.
The cytotoxicity of PTL and CTX on Lewis lung cancer cells (LLC cells) was assessed by measuring cell activity and apoptosis. The anti-tumor efficiency was evaluated using a tumor xenograft mice model, and the survival of mice and tumor volume were monitored. Additionally, the collected tumor tissues were analyzed for tumor microenvironment indicators and inflammatory factors.
In vitro, PTL demonstrated a synergistic effect with CTX in inhibiting the growth of LLC cells and promoting apoptosis. In vivo, metronomic chemotherapy com
PTL is an efficient compound that enhances the metronomic chemotherapy effects of CTX both in vitro and in vivo, suggesting its potential as a supplementary therapeutic strategy in metronomic chemotherapy to improve the chemotherapy effects.
Core Tip: Our present study found that as a specific inhibitor of NF-kB, Parthenolide can promote the efficiency of cyclophosphamide in lung cancer via inhibiting NF-kB signaling in vitro and in vivo. Our present study will help scientists and clinicians to draw up novel rhythmic chemotherapy strategies.